Thomas Jefferson University

Alexander Niyazov

TitleAdjunct Faculty
InstitutionThomas Jefferson University
DepartmentSchool Of Population Health
AddressNA
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Castro E, Wang D, Walsh S, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2024 Dec 07. PMID: 39645562.
      Citations:    
    2. Castro E, Figliuzzi R, Walsh S, Craigie S, Nazari J, Niyazov A, Samjoo IA. Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer. Oncologist. 2024 Nov 26. PMID: 39589223.
      Citations:    
    3. Castro E, Ellis J, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer. Oncologist. 2024 Oct 19. PMID: 39427229.
      Citations:    
    4. Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. Future Oncol. 2024; 20(30):2225-2231. PMID: 39451095.
      Citations:    
    5. Samjoo IA, Disher T, Castro E, Ellis J, Paganelli S, Nazari J, Niyazov A. Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2024 Jun 12; 22(5):102137. PMID: 38991256.
      Citations:    
    6. Shore ND, Broder MS, Barata PC, Crispino T, Fay AP, Lloyd J, Mellado B, Matsubara N, Pfanzelter N, Schlack K, Sieber P, Soares A, Dalglish H, Niyazov A, Shaman S, Zielinski MA, Chang J, Agarwal N. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. Eur Urol Oncol. 2024 Jun 11. PMID: 38866640.
      Citations:    
    7. Obeid E, Parikh RC, Esterberg E, Arondekar B, Hitchens A, Arruda LS, Niyazov A, Whitaker K. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline BRCA1/2-mutated, HER2-negative advanced breast cancer: a retrospective medical record review in the United States. Front Oncol. 2024; 14:1341665. PMID: 38817906.
      Citations:    
    8. Barata PC, Assayag J, Li B, Siu G, Niyazov A. Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2024 May 02. PMID: 38696212.
      Citations:    
    9. Bobbili PJ, Ivanova J, Solit DB, Mettu NB, McCall SJ, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Lam P, Muthukumar A, Guo T, Mohan M, Zhang A, Duh MS, Oh WK. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations. Clin Genitourin Cancer. 2024 Jun; 22(3):102080. PMID: 38653037.
      Citations:    
    10. Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncol. 2023 Oct 26. PMID: 37882449.
      Citations:    
    11. Freedland SJ, Samjoo IA, Rosta E, Lansing A, Worthington E, Niyazov A, Nazari J, Arondekar B. The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis. 2023 09; 26(3):461-474. PMID: 37592001.
      Citations:    
    12. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli ML. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 Jun 15. PMID: 37318349.
      Citations:    
    13. Barata PC, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, Ivanova J, Niyazov A. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study. Oncologist. 2023 Apr 04. PMID: 37014097.
      Citations:    
    14. Barata PC, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, Ivanova J, Niyazov A. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study. Oncologist. 2023 Apr 04. PMID: 37014080.
      Citations:    
    15. Zimmerman Savill KM, Ivanova J, Asgarisabet P, Falkenstein A, Balanean A, Niyazov A, Ryan JC, Kish J, Gajra A, Mahtani RL. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer. Oncologist. 2023 Mar 23. PMID: 36952230.
      Citations:    
    16. Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC Cancer. 2022 Dec 22; 22(1):1343. PMID: 36550413.
      Citations:    
    17. Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel. Cancers (Basel). 2022 Nov 02; 14(21). PMID: 36358816.
      Citations:    
    18. Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP. Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor?2-Negative Advanced Breast Cancer in the United States, Europe, and Israel. Adv Ther. 2023 Jan; 40(1):331-348. PMID: 36333567.
      Citations:    
    19. Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2?Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. Breast. 2022 Dec; 66:236-244. PMID: 36368161.
      Citations:    
    20. Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. Eur Urol. 2022 Jun 21. PMID: 35750582.
      Citations:    
    21. Lux MP, Lewis K, Rider A, Niyazov A. Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries. Breast Care (Basel). 2022 Oct; 17(5):460-469. PMID: 36684399.
      Citations:    
    22. Lux MP, Lewis K, Rider A, Niyazov A. Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer. Future Oncol. 2022 Mar; 18(9):1089-1101. PMID: 35098723.
      Citations:    
    23. Oderda G, Brixner D, Biskupiak J, Burgoyne D, Arondekar B, Deal LS, Quek RG, Niyazov A. Payer perceptions on the use of patient-reported outcomes in oncology decision making. J Manag Care Spec Pharm. 2022 Feb; 28(2):188-195. PMID: 34806908.
      Citations:    
    24. Biskupiak J, Oderda G, Brixner D, Burgoyne D, Arondekar B, Niyazov A. Payer perceptions on the use of economic models in oncology decision making. J Manag Care Spec Pharm. 2021 Nov; 27(11):1560-1567. PMID: 34714111.
      Citations:    
    25. Arondekar B, Duh MS, Bhak RH, DerSarkissian M, Huynh L, Wang K, Wojciehowski J, Wu M, Wornson B, Niyazov A, Demetri GD. Real-world Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. Clin Cancer Res. 2021 Oct 19. PMID: 34667027.
      Citations:    
    26. Zou D, Niyazov A, Arondekar B, Wu S. RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. Breast. 2021 Oct 13. PMID: 34657754.
      Citations:    
    27. Brixner D, Biskupiak J, Oderda G, Burgoyne D, Malone DC, Arondekar B, Niyazov A. Payer perceptions of the use of real-world evidence in oncology-based decision making. J Manag Care Spec Pharm. 2021 Aug; 27(8):1096-1105. PMID: 34337998.
      Citations:    
    28. Lux MP, Decker T, Runkel ED, Niyazov A, Quek RGW, Marschner N, Harbeck N. Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany. Breast Care (Basel). 2022 Feb; 17(1):40-46. PMID: 35350106.
      Citations:    
    29. Niyazov A, Lenci D. Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance. Front Public Health. 2018; 6:304. PMID: 30488029.
      Citations:    
    30. Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. J Manag Care Spec Pharm. 2017 Jul; 23(7):771-780. PMID: 28650249.
      Citations:    
    Niyazov's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (52)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _